NCT02364804View on ClinicalTrials.gov

A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer

CompletedOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

March 31, 2015

Study Completion Date

September 30, 2015

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Aprepitant

The incidence and grade of chemotherapy-induced nausea and vomit (CINV) will be assessed in patients receiving Aprepitant for the prevention of CINV upon the combination chemotherapy of nedaplatin and docetaxel for NSCLC. These data will be compared with those surveyed retrospectively in patients who had received the combination chemotherapy with anti-emetic agents but Aprepitant.

Trial Locations (1)

520-2192

Shiga University of Medical Science Hospital, Ōtsu

All Listed Sponsors
lead

Shiga University

OTHER

NCT02364804 - A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter